Previous 10 | Next 10 |
vTv Therapeutics press release (NASDAQ:VTVT): Q1 GAAP EPS of -$0.10. Revenue of $2M (+100.0% Y/Y). The Company’s cash position as of March 31, 2022, was $12.1 million compared to $13.4 million as of December 31, 2021. For further details see: vTv Therapeutics GAAP EPS of -$0.10, ...
HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs. Recent Achievements and Outlook Corporat...
vTv Therapeutics press release (NASDAQ:VTVT): Q4 GAAP EPS of -$0.11. Revenue of $9K The Company's cash position as of December 31, 2021, was $13.4M compared to $19.6M as of September 30, 2021. For further details see: vTv Therapeutics GAAP EPS of -$0.11
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update PR Newswire HIGH POINT, N.C. , March 29, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fo...
vTv Therapeutics (NASDAQ:VTVT) has appointed Rich Nelson as Acting CEO. Mr. Nelson joined the vTv Board of Directors in 2020, and currently serves as EVP Corporate & Business Development of Vericast, and EVP Corporate Development for MacAndrews & Forbes. Deepa Prasad, who has been ser...
vTv Therapeutics Announces CEO Transition PR Newswire HIGH POINT, N.C. , March 3, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diab...
3 Penny Stocks For Your Watchlist This Week Buying penny stocks or blue chips right now is not for the faint of heart. While there are a lot of opportunities to make money with penny stocks right now, investors have to have a complete understanding of the current market. For that re...
We discussed this trend on Thursday thanks to the attention that was sparked by shares of ISPO stock. Low float penny stocks are gaining even more attention in the stock market today thanks to the massive breakout potential that they can hold. In looking at the ISPO example, the small-c...
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a...
Can-Fite BioPharma (NYSE:CANF) +71% liver cancer patient treated with can-Fite’s Namodenoson clears all cancer lesions under open label extension of phase II study. Society Pass Incorporated (NASDAQ:SOPA) +35% on being added to the Russell 2000 Index. Verso (NYSE:VRS) +3...
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...